fluvastatin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antihyperlipidaemic substances, HMG CoA reductase inhibitors	1229	93957-54-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: lescol fluvastatin leschol fluvastatin sodium XU-62-320 fluvastatin sodium salt fluvastatin sodium hydrate	An indole-heptanoic acid derivative that inhibits HMG COA REDUCTASE and is used to treat HYPERCHOLESTEROLEMIA. In contrast to other statins, it does not appear to interact with other drugs that inhibit CYP3A4. Molecular weight: 411.47 Formula: C24H26FNO4 CLOGP: 4.05 LIPINSKI: 0 HAC: 5 HDO: 3 TPSA: 82.69 ALOGS: -4.97 ROTB: 8 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

lescol
fluvastatin
leschol
fluvastatin sodium
XU-62-320
fluvastatin sodium salt
fluvastatin sodium hydrate

An indole-heptanoic acid derivative that inhibits HMG COA REDUCTASE and is used to treat HYPERCHOLESTEROLEMIA. In contrast to other statins, it does not appear to interact with other drugs that inhibit CYP3A4.

Molecular weight: 411.47
Formula: C24H26FNO4
CLOGP: 4.05
LIPINSKI: 0
HAC: 5
HDO: 3
TPSA: 82.69
ALOGS: -4.97
ROTB: 8

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
60	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	50 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	1.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	1.62 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	24 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.42 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	16 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.01 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.70 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 31, 1993	FDA	NOVARTIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myalgia	155.86	15.25	144	8898	146385	63333595
Rhabdomyolysis	127.85	15.25	79	8963	43872	63436108
Blood creatine phosphokinase increased	118.28	15.25	66	8976	30364	63449616
Limb reduction defect	101.87	15.25	21	9021	405	63479575
Dysmorphism	75.18	15.25	23	9019	2273	63477707
Cleft palate	73.91	15.25	19	9023	993	63478987
Gamma-glutamyltransferase increased	67.01	15.25	48	8994	33983	63445997
Atrial septal defect	66.67	15.25	28	9014	6910	63473070
Talipes	66.01	15.25	19	9023	1521	63478459
Antinuclear antibody negative	64.61	15.25	13	9029	221	63479759
Patent ductus arteriosus	61.30	15.25	23	9019	4227	63475753
Limb hypoplasia congenital	60.03	15.25	12	9030	197	63479783
Coombs positive haemolytic anaemia	58.63	15.25	13	9029	358	63479622
Congenital oral malformation	54.18	15.25	11	9031	196	63479784
Alanine aminotransferase increased	53.82	15.25	70	8972	103700	63376280
Drug ineffective	53.04	15.25	43	8999	1044722	62435258
Retrognathia	50.76	15.25	12	9030	442	63479538
Aspartate aminotransferase increased	50.12	15.25	63	8979	90214	63389766
Herpes simplex reactivation	48.08	15.25	12	9030	556	63479424
Acute kidney injury	46.14	15.25	110	8932	263305	63216675
Developmental hip dysplasia	46.01	15.25	14	9028	1358	63478622
Myopathy	42.71	15.25	24	9018	11167	63468813
Antiphospholipid syndrome	42.35	15.25	14	9028	1776	63478204
Gastritis haemorrhagic	40.26	15.25	13	9029	1532	63478448
Neck deformity	36.22	15.25	13	9029	2108	63477872
Lactic acidosis	35.57	15.25	35	9007	38252	63441728
Pancreatitis acute	35.35	15.25	30	9012	27136	63452844
Complex regional pain syndrome	34.88	15.25	13	9029	2344	63477636
Anxiety disorder	34.46	15.25	15	9027	4035	63475945
Jaundice	33.43	15.25	30	9012	29221	63450759
Off label use	32.58	15.25	29	9013	674433	62805547
Interstitial lung disease	30.89	15.25	41	9001	61867	63418113
Drug interaction	30.13	15.25	86	8956	229045	63250935
Premature baby	29.26	15.25	24	9018	20711	63459269
Aplasia	27.46	15.25	13	9029	4246	63475734
Blood alkaline phosphatase increased	27.09	15.25	32	9010	42935	63437045
Hyperlipidaemia	26.26	15.25	22	9020	19549	63460431
Immunosuppressant drug level increased	26.24	15.25	12	9030	3626	63476354
Muscle spasms	24.93	15.25	63	8979	156087	63323893
Alopecia	24.08	15.25	9	9033	337527	63142453
Coronary artery disease	23.61	15.25	26	9016	32351	63447629
Muscular weakness	23.45	15.25	53	8989	122300	63357680
Joint swelling	22.93	15.25	9	9033	327657	63152323
Peripheral swelling	22.81	15.25	5	9037	265937	63214043
Erysipelas	22.42	15.25	14	9028	7891	63472089
Blood creatinine increased	21.43	15.25	42	9000	87802	63392178
Pulmonary artery stenosis	20.89	15.25	5	9037	194	63479786
Chromaturia	20.81	15.25	18	9024	16699	63463281
Haematoma	20.42	15.25	25	9017	34795	63445185
Neonatal seizure	20.42	15.25	6	9036	516	63479464
Hypernatraemia	20.39	15.25	13	9029	7596	63472384
Osteonecrosis	20.18	15.25	21	9021	24509	63455471
Cerebrovascular accident	19.82	15.25	46	8996	107978	63372002
Pleuritic pain	19.75	15.25	13	9029	8016	63471964
Angiosclerosis	19.41	15.25	3	9039	9	63479971
Product use issue	19.21	15.25	4	9038	220516	63259464
Hepatic function abnormal	19.14	15.25	25	9017	37117	63442863
Blood urea increased	18.91	15.25	21	9021	26358	63453622
Cholestasis	18.68	15.25	22	9020	29412	63450568
Otospondylomegaepiphyseal dysplasia	18.57	15.25	4	9038	96	63479884
Hypothyroidism	17.91	15.25	26	9016	42606	63437374
Ocular myasthenia	17.14	15.25	4	9038	139	63479841
Synovitis	17.10	15.25	3	9039	186915	63293065
Sterile pyuria	16.98	15.25	3	9039	24	63479956
Bradycardia neonatal	16.88	15.25	6	9036	946	63479034
Cerebral ischaemia	16.81	15.25	11	9031	6717	63473263
Nephroangiosclerosis	16.55	15.25	4	9038	162	63479818
Therapeutic product effect decreased	15.83	15.25	4	9038	193183	63286797
Amyotrophic lateral sclerosis	15.71	15.25	6	9036	1157	63478823
Shock	15.66	15.25	18	9024	23445	63456535
Fasciitis	15.58	15.25	5	9037	577	63479403
Product dose omission issue	15.48	15.25	7	9035	234306	63245674
Depression	15.37	15.25	62	8980	196430	63283550

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myalgia	300.27	16.94	218	9198	83892	34863623
Blood creatine phosphokinase increased	163.59	16.94	118	9298	44739	34902776
Rectal prolapse	90.62	16.94	22	9394	470	34947045
Renal cyst haemorrhage	84.91	16.94	22	9394	617	34946898
Intraductal papillary mucinous neoplasm	78.82	16.94	20	9396	515	34947000
Myopathy	78.42	16.94	45	9371	11509	34936006
Muscle rupture	71.84	16.94	26	9390	2272	34945243
SARS-CoV-2 antibody test positive	68.18	16.94	17	9399	407	34947108
Vena cava injury	66.72	16.94	16	9400	324	34947191
Abdominal wall haemorrhage	65.74	16.94	17	9399	473	34947042
Off label use	62.42	16.94	18	9398	419506	34528009
Carotid arteriosclerosis	61.76	16.94	22	9394	1836	34945679
Delayed graft function	61.56	16.94	23	9393	2198	34945317
Aortic dilatation	59.80	16.94	20	9396	1381	34946134
Vascular anastomotic haemorrhage	58.87	16.94	14	9402	273	34947242
Diverticulum intestinal	57.75	16.94	26	9390	3995	34943520
Perineal cyst	54.40	16.94	13	9403	259	34947256
Renal artery stenosis	53.98	16.94	21	9395	2240	34945275
Mean cell volume increased	50.36	16.94	22	9394	3147	34944368
Vascular compression	50.22	16.94	13	9403	363	34947152
Gamma-glutamyltransferase increased	48.55	16.94	49	9367	29182	34918333
Restless legs syndrome	47.42	16.94	29	9387	8325	34939190
Hyperparathyroidism secondary	46.25	16.94	17	9399	1551	34945964
Actinic keratosis	45.61	16.94	23	9393	4544	34942971
Aortic arteriosclerosis	45.28	16.94	23	9393	4613	34942902
Hepatosplenomegaly	44.60	16.94	22	9394	4147	34943368
Spinal stenosis	42.51	16.94	23	9393	5246	34942269
Glycosylated haemoglobin increased	41.58	16.94	30	9386	11330	34936185
Amyotrophic lateral sclerosis	41.35	16.94	14	9402	1004	34946511
Intervertebral disc space narrowing	40.86	16.94	14	9402	1041	34946474
Rhabdomyolysis	40.85	16.94	69	9347	68094	34879421
Blood 25-hydroxycholecalciferol decreased	39.35	16.94	10	9406	259	34947256
Vertigo	39.13	16.94	41	9375	25495	34922020
Dysuria	38.79	16.94	42	9374	27110	34920405
Left ventricular hypertrophy	38.09	16.94	25	9391	8105	34939410
Spinal osteoarthritis	36.91	16.94	24	9392	7659	34939856
Swelling of eyelid	36.34	16.94	13	9403	1098	34946417
Arteriosclerosis	35.78	16.94	28	9388	11940	34935575
Ureteric injury	35.75	16.94	7	9409	51	34947464
Haemorrhoids	34.97	16.94	30	9386	14545	34932970
Vitamin D decreased	33.23	16.94	17	9399	3459	34944056
Myocardial infarction	32.12	16.94	88	9328	120997	34826518
Vestibular neuronitis	31.38	16.94	8	9408	210	34947305
General physical health deterioration	29.92	16.94	89	9327	128180	34819335
Blood potassium increased	29.88	16.94	29	9387	16466	34931049
Activated partial thromboplastin time prolonged	29.64	16.94	22	9394	8673	34938842
Benign prostatic hyperplasia	29.14	16.94	27	9389	14468	34933047
Death	29.03	16.94	39	9377	398010	34549505
Face oedema	28.23	16.94	24	9392	11492	34936023
Squamous cell carcinoma of skin	27.34	16.94	23	9393	10858	34936657
Toxicity to various agents	27.21	16.94	10	9406	200352	34747163
Tendon rupture	26.77	16.94	19	9397	6993	34940522
Aspartate aminotransferase increased	26.23	16.94	57	9359	67726	34879789
Angina pectoris	26.14	16.94	37	9379	31326	34916189
Fear	26.02	16.94	22	9394	10454	34937061
Hepatic steatosis	25.52	16.94	28	9388	18334	34929181
Chronic kidney disease	25.04	16.94	42	9374	41168	34906347
Generalised oedema	24.73	16.94	23	9393	12385	34935130
Febrile bone marrow aplasia	24.09	16.94	19	9397	8190	34939325
Coronary artery disease	23.90	16.94	45	9371	48260	34899255
Complications of transplanted kidney	23.63	16.94	15	9401	4594	34942921
Presyncope	22.98	16.94	27	9389	19032	34928483
Large intestine polyp	22.55	16.94	18	9398	7896	34939619
Aortic valve incompetence	22.54	16.94	16	9400	5888	34941627
Product dose omission issue	22.17	16.94	3	9413	119708	34827807
Systemic infection	19.61	16.94	14	9402	5198	34942317
Perioral dermatitis	19.20	16.94	5	9411	143	34947372
Seizure	18.55	16.94	3	9413	104854	34842661
Myocardial ischaemia	18.28	16.94	23	9393	17385	34930130
Congenital inguinal hernia	18.12	16.94	5	9411	179	34947336
Funguria	18.06	16.94	4	9412	56	34947459
Atrioventricular block first degree	17.66	16.94	14	9402	6078	34941437
Basal cell carcinoma	17.58	16.94	24	9392	19634	34927881

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myalgia	350.19	14.46	283	14477	185358	79544270
Blood creatine phosphokinase increased	251.52	14.46	155	14605	65935	79663693
Rhabdomyolysis	121.89	14.46	121	14639	103010	79626618
Myopathy	112.15	14.46	61	14699	20502	79709126
Renal cyst haemorrhage	91.36	14.46	22	14738	670	79728958
Off label use	88.65	14.46	29	14731	907186	78822442
Gamma-glutamyltransferase increased	85.48	14.46	75	14685	54605	79675023
Intraductal papillary mucinous neoplasm	78.33	14.46	20	14740	778	79728850
SARS-CoV-2 antibody test positive	73.93	14.46	17	14743	422	79729206
Vena cava injury	72.13	14.46	16	14744	336	79729292
Rectal prolapse	66.41	14.46	22	14738	2156	79727472
Abdominal wall haemorrhage	66.19	14.46	17	14743	677	79728951
Carotid arteriosclerosis	65.96	14.46	23	14737	2633	79726995
Vascular anastomotic haemorrhage	64.10	14.46	14	14746	273	79729355
Aspartate aminotransferase increased	63.24	14.46	101	14659	138540	79591088
Delayed graft function	59.72	14.46	23	14737	3484	79726144
Perineal cyst	59.40	14.46	13	14747	256	79729372
Aortic dilatation	58.05	14.46	19	14741	1793	79727835
Amyotrophic lateral sclerosis	58.02	14.46	19	14741	1796	79727832
Muscle rupture	54.88	14.46	22	14738	3705	79725923
Actinic keratosis	53.81	14.46	25	14735	6017	79723611
Renal artery stenosis	52.82	14.46	21	14739	3461	79726167
Alanine aminotransferase increased	52.79	14.46	102	14658	162468	79567160
Vascular compression	49.60	14.46	13	14747	561	79729067
Myocardial infarction	46.28	14.46	104	14656	184025	79545603
Diverticulum intestinal	45.45	14.46	25	14735	8580	79721048
Aortic arteriosclerosis	44.61	14.46	25	14735	8893	79720735
Hepatosplenomegaly	44.58	14.46	22	14738	6047	79723581
Mean cell volume increased	43.96	14.46	22	14738	6231	79723397
Hyperparathyroidism secondary	43.71	14.46	17	14743	2643	79726985
Benign prostatic hyperplasia	43.50	14.46	27	14733	11585	79718043
Coronary artery disease	41.90	14.46	56	14704	65418	79664210
Blood 25-hydroxycholecalciferol decreased	39.41	14.46	10	14750	379	79729249
Intervertebral disc space narrowing	39.18	14.46	14	14746	1721	79727907
Activated partial thromboplastin time prolonged	36.19	14.46	26	14734	14202	79715426
Arteriosclerosis	34.65	14.46	28	14732	18199	79711429
Left ventricular hypertrophy	34.45	14.46	23	14737	11168	79718460
Joint swelling	34.38	14.46	6	14754	288640	79440988
Blood potassium increased	33.89	14.46	34	14726	29241	79700387
Glycosylated haemoglobin increased	33.30	14.46	28	14732	19232	79710396
Toxicity to various agents	32.30	14.46	19	14741	421521	79308107
Spinal osteoarthritis	32.17	14.46	26	14734	16901	79712727
Squamous cell carcinoma of skin	31.98	14.46	24	14736	14009	79715619
Ureteric injury	31.69	14.46	7	14753	144	79729484
Peripheral swelling	31.26	14.46	6	14754	269611	79460017
Acute kidney injury	31.19	14.46	183	14577	519221	79210407
Drug ineffective	30.37	14.46	101	14659	1080812	78648816
Complications of transplanted kidney	29.56	14.46	17	14743	6349	79723279
Completed suicide	29.51	14.46	5	14755	245762	79483866
Spinal stenosis	29.47	14.46	24	14736	15767	79713861
Infusion related reaction	29.20	14.46	4	14756	230233	79499395
Lactic acidosis	29.00	14.46	49	14711	70310	79659318
Jaundice	28.71	14.46	42	14718	53307	79676321
Haemorrhoids	28.64	14.46	31	14729	29097	79700531
Swelling of eyelid	28.54	14.46	14	14746	3797	79725831
Death	28.44	14.46	38	14722	566476	79163152
Fear	28.18	14.46	27	14733	21959	79707669
Myoglobin blood increased	27.94	14.46	13	14747	3138	79726490
Cerebrovascular accident	27.70	14.46	77	14683	155215	79574413
Dysuria	27.26	14.46	40	14720	50911	79678717
Chronic kidney disease	27.17	14.46	46	14714	66108	79663520
Blood alkaline phosphatase increased	27.12	14.46	45	14715	63619	79666009
Vertigo	27.01	14.46	47	14713	69035	79660593
Restless legs syndrome	26.37	14.46	25	14735	20067	79709561
Muscular weakness	26.05	14.46	77	14683	160652	79568976
General physical health deterioration	24.97	14.46	109	14651	275129	79454499
Muscle spasms	24.87	14.46	80	14680	174650	79554978
Hyperkalaemia	24.77	14.46	61	14699	114337	79615291
Drug interaction	24.71	14.46	146	14614	415037	79314591
Vestibular neuronitis	24.65	14.46	8	14752	735	79728893
Blood creatinine increased	23.92	14.46	73	14687	154984	79574644
Product dose omission issue	23.90	14.46	8	14752	247529	79482099
Hepatic function abnormal	23.85	14.46	46	14714	73061	79656567
Tendon rupture	23.84	14.46	19	14741	12107	79717521
Hepatic steatosis	23.71	14.46	32	14728	37706	79691922
Aortic valve incompetence	23.29	14.46	17	14743	9513	79720115
Renal impairment	23.15	14.46	73	14687	157710	79571918
Myocardial ischaemia	23.08	14.46	26	14734	25493	79704135
Large intestine polyp	23.06	14.46	19	14741	12689	79716939
Vitamin D decreased	22.98	14.46	17	14743	9708	79719920
Face oedema	22.66	14.46	27	14733	28109	79701519
Pancreatitis acute	22.39	14.46	36	14724	49568	79680060
Immunosuppressant drug level increased	21.83	14.46	16	14744	9011	79720617
Presyncope	21.63	14.46	32	14728	41022	79688606
Blood urea increased	21.47	14.46	35	14725	48755	79680873
Product use in unapproved indication	21.05	14.46	10	14750	250349	79479279
Product use issue	19.88	14.46	7	14753	209815	79519813
Chromaturia	19.58	14.46	24	14736	25722	79703906
Muscle necrosis	19.39	14.46	8	14752	1450	79728178
Atrioventricular block first degree	19.24	14.46	17	14743	12474	79717154
Metabolic acidosis	18.92	14.46	45	14715	82484	79647144
Renal cyst	18.71	14.46	18	14742	14714	79714914
General physical condition	18.63	14.46	3	14757	9	79729619
Intentional product use issue	18.46	14.46	3	14757	152109	79577519
Alopecia	18.31	14.46	10	14750	231345	79498283
Autoimmune hepatitis	18.07	14.46	16	14744	11767	79717861
Rheumatoid arthritis	18.03	14.46	8	14752	208462	79521166
Angiosclerosis	17.77	14.46	3	14757	13	79729615
Atrial fibrillation	17.65	14.46	78	14682	197808	79531820
Acute myocardial infarction	16.59	14.46	41	14719	76995	79652633
Systemic infection	16.49	14.46	14	14746	9738	79719890
Interstitial lung disease	16.42	14.46	52	14708	112548	79617080
Perioral dermatitis	16.37	14.46	5	14755	377	79729251
Blood creatine phosphokinase MB	16.31	14.46	3	14757	23	79729605
Haematoma	16.00	14.46	32	14728	52163	79677465
Blood lactate dehydrogenase increased	15.76	14.46	27	14733	39143	79690485
Febrile bone marrow aplasia	14.84	14.46	15	14745	13005	79716623
Lower respiratory tract infection	14.70	14.46	3	14757	129217	79600411

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C10AA04	CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, PLAIN HMG CoA reductase inhibitors
FDA MoA	N0000000121	Hydroxymethylglutaryl-CoA Reductase Inhibitors
FDA EPC	N0000175589	HMG-CoA Reductase Inhibitor
CHEBI has role	CHEBI:35679	antilipemic drugs
CHEBI has role	CHEBI:77255	lethal toxin inhibitors
CHEBI has role	CHEBI:35821	anticholesteremic drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypercholesterolemia	indication	13644009
Arteriosclerotic vascular disease	indication	72092001
Familial hypercholesterolemia - heterozygous	indication	238079002
Mixed hyperlipidemia	indication	267434003
Slow Progression of Coronary Artery Disease	indication
Cerebrovascular accident	off-label use	230690007
Myocardial Infarction Prevention	off-label use
Primary Prevention of Coronary Heart Disease	off-label use
Prevention of Transient Ischemic Attacks	off-label use
Alcoholism	contraindication	7200002
Low blood pressure	contraindication	45007003
Acute nephropathy	contraindication	58574008
Disorder of muscle	contraindication	129565002	DOID:423
Liver function tests abnormal	contraindication	166603001
Hemorrhagic cerebral infarction	contraindication	230706003
Disease of liver	contraindication	235856003	DOID:409
Rhabdomyolysis	contraindication	240131006
Pregnancy, function	contraindication	289908002
Surgical procedure	contraindication	387713003
Breastfeeding (mother)	contraindication	413712001
Traumatic injury	contraindication	417746004
Uncontrolled Epilepsy	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.05	acidic
pKa2	13.34	acidic
pKa3	13.99	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
3-hydroxy-3-methylglutaryl-coenzyme A reductase	Enzyme	P04035	HMDH_HUMAN	INHIBITOR	IC50	7.55	CHEMBL	DRUG LABEL
Cytochrome P450 2C9	Enzyme	P11712	CP2C9_HUMAN		IC50	6.40	DRUG MATRIX
Retinoic acid receptor RXR-alpha	Nuclear hormone receptor	P19793	RXRA_HUMAN		Kd	4.96	CHEMBL
Nuclear receptor subfamily 1 group I member 3	Nuclear hormone receptor	Q14994	NR1I3_HUMAN				WOMBAT-PK
Nuclear receptor subfamily 4 group A member 2	Nuclear other	P43354	NR4A2_HUMAN		EC50	5.72	CHEMBL
NAD-dependent protein deacetylase sirtuin-6	Unclassified	Q8N6T7	SIR6_HUMAN		EC50	5.15	CHEMBL
Sodium/bile acid cotransporter	Transporter	Q14973	NTCP_HUMAN		IC50	4.40	CHEMBL
3-hydroxy-3-methylglutaryl-coenzyme A reductase	Enzyme		HMDH_RAT		IC50	8.60	CHEMBL

External reference:

ID	Source
D00892	KEGG_DRUG
93957-55-2	SECONDARY_CAS_RN
4020854	VANDF
4023909	VANDF
C0082608	UMLSCUI
CHEBI:38561	CHEBI
115	PDB_CHEM_ID
CHEMBL2220442	ChEMBL_ID
CHEMBL1078	ChEMBL_ID
CHEMBL2218894	ChEMBL_ID
D000077340	MESH_DESCRIPTOR_UI
DB01095	DRUGBANK_ID
23663976	PUBCHEM_CID
2951	IUPHAR_LIGAND_ID
6547	INN_ID
4L066368AS	UNII
151972	RXNORM
1724	MMSL
189348	MMSL
4757	MMSL
d03183	MMSL
004439	NDDF
004440	NDDF
387585004	SNOMEDCT_US
412392009	SNOMEDCT_US
96307003	SNOMEDCT_US
CHEMBL103585	ChEMBL_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
LescolXL	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0354	TABLET, EXTENDED RELEASE	80 mg	ORAL	NDA	30 sections
LescolXL	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0354	TABLET, EXTENDED RELEASE	80 mg	ORAL	NDA	30 sections
LescolXL	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0354	TABLET, EXTENDED RELEASE	80 mg	ORAL	NDA	30 sections
Fluvastatin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7442	CAPSULE	20 mg	ORAL	ANDA	26 sections
Fluvastatin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7442	CAPSULE	20 mg	ORAL	ANDA	26 sections
Fluvastatin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7443	CAPSULE	40 mg	ORAL	ANDA	26 sections
Fluvastatin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7443	CAPSULE	40 mg	ORAL	ANDA	26 sections
Fluvastatin Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7446	TABLET, FILM COATED, EXTENDED RELEASE	80 mg	ORAL	ANDA	28 sections
Fluvastatin Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7446	TABLET, FILM COATED, EXTENDED RELEASE	80 mg	ORAL	ANDA	28 sections
Fluvastatin Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0378-8020	CAPSULE	20 mg	ORAL	ANDA	26 sections
Fluvastatin Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0378-8021	CAPSULE	40 mg	ORAL	ANDA	26 sections
Fluvastatin Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0527-2580	TABLET, FILM COATED, EXTENDED RELEASE	80 mg	ORAL	ANDA	30 sections
Fluvastatin Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0527-2580	TABLET, FILM COATED, EXTENDED RELEASE	80 mg	ORAL	ANDA	30 sections
FLUVASTATIN SODIUMER	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8017	TABLET, EXTENDED RELEASE	80 mg	ORAL	NDA authorized generic	27 sections
FLUVASTATIN SODIUMER	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8017	TABLET, EXTENDED RELEASE	80 mg	ORAL	NDA authorized generic	27 sections
LESCOL	HUMAN PRESCRIPTION DRUG LABEL	1	54868-3329	CAPSULE	20 mg	ORAL	NDA	15 sections
LESCOL	HUMAN PRESCRIPTION DRUG LABEL	1	54868-4224	CAPSULE	40 mg	ORAL	NDA	15 sections
LESCOL XL	HUMAN PRESCRIPTION DRUG LABEL	1	54868-4601	TABLET, EXTENDED RELEASE	80 mg	ORAL	NDA	15 sections
Fluvastatin	HUMAN PRESCRIPTION DRUG LABEL	1	63629-8737	CAPSULE	40 mg	ORAL	ANDA	26 sections
Fluvastatin	HUMAN PRESCRIPTION DRUG LABEL	1	63629-8737	CAPSULE	40 mg	ORAL	ANDA	26 sections
Fluvastatin	HUMAN PRESCRIPTION DRUG LABEL	1	63629-8737	CAPSULE	40 mg	ORAL	ANDA	26 sections
Fluvastatin	HUMAN PRESCRIPTION DRUG LABEL	1	63629-8812	CAPSULE	20 mg	ORAL	ANDA	26 sections
Fluvastatin	HUMAN PRESCRIPTION DRUG LABEL	1	63629-8812	CAPSULE	20 mg	ORAL	ANDA	26 sections
Fluvastatin Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	68151-1326	CAPSULE	20 mg	ORAL	ANDA	25 sections
Fluvastatin Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	68151-1334	CAPSULE	40 mg	ORAL	ANDA	25 sections
Lescol XL	HUMAN PRESCRIPTION DRUG LABEL	1	68151-4471	TABLET, EXTENDED RELEASE	80 mg	ORAL	NDA	26 sections